TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00814723
Drug: fluvastatin
Normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg MR, 12 weeks
Study: NCT00814723
Drug: Fluvastatin plus ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluvastatin 80 mg MR plus ezetimibe 10 mg
Study: NCT01353391
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg daily OD from randomisation for 2 weeks, then 1000mg BID throughout the duration of pregnancy
Study: NCT00003522
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Cancer of the Small Intestine will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT01307878
Drug: chemotherapy ± targeted therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimen with either mFOLFOX6 plus cetuximab, bevacizumab or mFOLFOX6 alone were allocated, according the RAS genotype and patient affordability.
Study: NCT02905045
Drug: Ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02905045
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04959409
Drug: Topical analgesia (EMLA or AMETOP)
Normalized name: ANALGESIC TOP GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whether topical analgesia has or has not been administered to each child prior to them receiving an inhalational induction of anaesthesia
Study: NCT02872233
Drug: BAY 987519
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
Study: NCT02872233
Drug: SPF 15 Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
Study: NCT00734708
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control
Study: NCT01504139
Drug: hCG(r-hCG, Ovitrelle, Merck-Serono, Hellerup, Denmark) in the late follicular phase + luteal phase
Approvals — FDA: no, EMA: no, PMDA: no
Description: when the follicles are over 12 mm FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark) is replaced by hCG (r-hCG, Ovitrelle,Merck-Serono, Hellerup,Denmark).
Study: NCT01504139
Drug: hCG(r-hCG, Ovitrelle,Merck-Serono, Hellerup, Denmark) in the follicular phase + luteal phase
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG(r-hCG,Ovitrelle,Merck-Serono, Hellerup, Denmark) is given together with FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark) from the beginning of the FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark)stimulation.
Study: NCT01504139
Drug: vaginal progesterone(Crinone; Merck-Serono, Hellerup, Denmark) and estradiol(Estrofem; Novo Nordisk, Copenhagen, Denmark) in the luteal phase
Normalized name: ESTRADIOL/PROGESTERONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: The usual dose of vaginal progesterone(Crinone; Merck-Serono, Hellerup, Denmark) and estradiol (Estrofem; Novo Nordisk, Copenhagen, Denmark) is given in the luteal phase-
Study: NCT04651491
Drug: Kagocel
Approvals — FDA: no, EMA: no, PMDA: no
Description: The researchers prescribed antiviral medications, including Kagocel, according to routine clinical practice. Patients who were assigned Kagocel were invited to participate in the study.~Kagocel administration:~1. for children from 3 to 6 years old (n=41): In the first 2 days - 1 tablet 2 times a day, in the next 2 days - 1 tablet once a day. Total for the course of administration 6 tablets within the period of 4 days.~2. for children from 6 years old (n=39) - administered in the first 2 days - 1 tablet 3 times a day, in the next 2 days - 1 tablet 2 times a day. Total for the course of administration 10 tablets within the period of 4 days.
Study: NCT03478462
Drug: CLR 131
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV dose of CLR 131, increased/decreased by dose level; single or fractionated dose
Study: NCT03679143
Drug: Placebo 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state.
Study: NCT03679143
Drug: ZSP1273 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP1273 tablets administered orally once daily under fasted condition
Study: NCT03679143
Drug: Placebo 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
Study: NCT03679143
Drug: ZSP1273 400 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP1273 tablets administered orally once daily in the fasting state
Study: NCT03679143
Drug: Placebo 400 mg
Normalized name: placebo 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state
Study: NCT03679143
Drug: ZSP1273 600 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP1273 tablets administered orally once daily under fasted condition
Study: NCT03679143
Drug: Placebo 600 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
Study: NCT03679143
Drug: ZSP1273 900 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP1273 tablets administered orally once daily in the fasting state
Study: NCT03679143
Drug: Placebo 900 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
Study: NCT03679143
Drug: ZSP1273 1200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP1273 tablets administered orally once daily in the fasting state
Study: NCT03679143
Drug: Placebo 1200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state
Study: NCT03679143
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition for 5 Days.
Study: NCT03679143
Drug: ZSP1273 Median Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
Study: NCT03679143
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
Study: NCT01718587
Drug: antiviral therapy (lamivudine, other antiviral drugs)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: lamivudine, 100 mg per day (oral dose); or adefovir dipivoxil 10 mg per day (oral dose); or grace entecavir 0.5-1mg per day (oral dose); or behalftelbivudine 600 mg per day (oral dose).
Study: NCT01666912
Drug: Contraceptive implant
Normalized name: Implanon Contraceptive Implant
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00412932
Drug: Olmesartan medoxomil/hydrochlorothiazide
Normalized name: olmesartan medoxomil/hydrochlorothiazide 40 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT01877668
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 1 tablet of 5 mg and placebo po 1 tablet BID x 9 months Placebo injections every 2 weeks x 12 months
Study: NCT00176657
Drug: HEMOBAG Assessment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04485663
Drug: ALG-010133
Normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or multiple doses of ALG-010133
Study: NCT04485663
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or multiple doses of Placebo
Study: NCT03190681
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral ingestion of 3 tablets in a single-dose
Study: NCT00002657
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 650 mg/m\^2
Study: NCT00002657
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m\^2
Study: NCT05833919
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine use in breast cancer is registered as monotherapy in advanced breast cancer after failure of a taxane- and anthracycline-containing chemotherapy or for patients for whom an anthracycline is contraindicated. Capecitabine is available in tablets of 150 and 500 mg. The recommended dose as a single agent is 1,250 mg/m2 b.i.d. (twice daily) for 14 days repeated on day 22. The tablets should be swallowed with water within 30 minutes after a meal. Caution is recommended in patients with ischemic heart disease or coronary artery disease and/or in therapy with sorivudine and analogs, coumarins, and phenytoin.
Study: NCT02090283
Drug: SD-101 dermal cream (6%)
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
Study: NCT03320265
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly treatment for 3 months (4 administrations)
Study: NCT01637714
Drug: Multi-strain probiotics
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: * B. longum BORI: 1 x 109~* B. bifidum BGN4: 1 x 109~* B. lactis AD011: 1 x 109~* B. infantis IBS007: 1 x 109~* Lactobacillus acidophilus AD031: 1 x 109~three times a day, within 10 minutes after meal, per oral with water
Study: NCT01637714
Drug: Placebo powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: same taste, shape, dosage as experimental drug~three times a day, within 10 minutes after meal, per oral with water
Study: NCT00003007
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002657
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 120 mg/m\^2
Study: NCT03592836
Drug: Loop Diuretics
Normalized name: LOOP DIURETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous administration of diuretics
Study: NCT01455584
Drug: HM781-36B tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q1X28D/4W for HM781-36B tablets
Study: NCT02258659
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02237989
Drug: paracetamol+native collagen type 2
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: paracetamol (1500 mg) + native collagen type 2 (10mg)
Study: NCT03029455
Drug: VX-659 Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03029455
Drug: Triple Combination (TC) Matching Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04724785
Drug: regimen change
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Based on ongoing one, regimen will be changed . The principle for adjusting anti-viral regimen is as follows: 1. The patients were treated with second-line drugs: changing ADV to ETV/TAF/TDF , changing LAM to TAF/TDF and changing LdT to TAF/TDF; 2. The patients were treated with ETV: adding or switching to TAF/TDF;3. TAF or ETV is recommended for patients with one or more TDF risk factors, such as \> 40 years old, patients with abnormal bone/kidney related indicators or patients with high risk of bone/kidney injuries.【ADV=adefovir dipivoxil, LAM=lamivudine, and LdT=telbivudine , TAF =Tenofovir alafenamide Fumarate, ETV=Entecavir and TDF=Tenofovir disoproxil fumarate 】
Study: NCT00551174
Drug: ibandronate [Bonviva/Boniva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg IV every 3 months for 3 years. All patients received a minimum of calcium 500 milligrams/day (upper limit 1500 mg/day) and Vitamin D 400 Internation Units/day (IU/day).
Study: NCT00551174
Drug: ibandronate [Bonviva/Boniva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg IV every 2 months for 3 years. All patients received a minimum of calcium 500 milligrams/day (upper limit 1500 mg/day) and Vitamin D 400 Internation Units/day (IU/day).
Study: NCT01534416
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects are injected paracervically with 10 ml of normal saline prior to surgical incision.
Study: NCT00004057
Drug: L-778,123
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00158262
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching propranolol short-acting or long-acting capsule
Study: NCT01808261
Drug: GSK249320 100/mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear to opalescent, colorless to pale yellow or pale brown, and is supplied as a sterile, concentrated solution (1000mg/vial). GSK249320 is for IV use only.
Study: NCT01223768
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice per day
Study: NCT02204345
Drug: RO5479599
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO5479599 will be administered as an intravenous infusion q3w until disease progression, death, unacceptable toxicity or withdrawal of consent.
Study: NCT00613379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBO, one IV dose (N=10)
Study: NCT02354092
Drug: Preprocedural pain control
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg Ibuprofen taken before dilator placement
Study: NCT02646319
Drug: Nanoparticle Albumin-Bound Rapamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT02580253
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin,Fluorouracil
Study: NCT04000126
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100ml 0,9% NaCl iv 10min before intubation
Study: NCT03295240
Drug: BR-I (bendamustine, rituximab, ibrutinib)
Normalized name: Respa-BR
Approvals — FDA: no, EMA: no, PMDA: no
Description: The BR-I (bendamustine, rituximab, ibrutinib) regimen will be administered for six 28-day cycles: bendamustine (90 mg/m2; (or 70mg/m2 for dose level -1); day 1 and 2 ), rituximab (375 mg/m2; day 1), and ibrutinib one pill or four 140mg capsules (560 mg oral daily; day 1-28).
Study: NCT03295240
Drug: VEN (Venetoclax)
Normalized name: Apis mellifera ven protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial cycle 1 VEN (Venetoclax) dose ramp-up will be: 20 mg daily for 1 week, 50 mg daily for week 2, 100 mg daily for week 3, and 200 mg daily for week 4. Thereafter, VEN will be administered at a fixed dose level of 400 mg daily for varying durations of each 28-day cycle. Now also include a -2 dose level which has the reduced 3-day duration of Ventoclax 400 mg daily.
Study: NCT03247088
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05285787
Drug: EPN-701 (Oral)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-7
Study: NCT00007995
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02601222
Drug: Runzao zhiyang capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Runzao zhiyang capsule：4 pills each time, 3 times a day, oral. Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
Study: NCT02601222
Drug: Urea cream
Normalized name: Amino Acid-Urea Cream
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application, apply to the affected area and gently rub, 2 times a day.Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
Study: NCT04265261
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral placebo matched to RG7774
Study: NCT04265261
Drug: RG7774
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral RG7774
Study: NCT02182986
Drug: Immunosuppressive Drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive drugs prescribed as standard of care to prevent rejection of the allograft.
Study: NCT01681953
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusions weekly
Study: NCT01084148
Drug: V0034CR01B
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01084148
Drug: V0034CR01B vehicle
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02757352
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT00497146
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule
Study: NCT01736735
Drug: CLP
Normalized name: Endopeptidase Clp
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01736735
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02155309
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00424593
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: every day (QD), by mouth (PO), 13 weeks
Study: NCT00568737
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride
Study: NCT00572455
Drug: PF-04217329 - Lowest Dose
Normalized name: Influenza, high-dose, quadrivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop of lowest dose PF-04217329, once a day, per dosed eye for duration of study.
Study: NCT00572455
Drug: PF-04217329 - Middle Dose
Normalized name: Influenza, high-dose, quadrivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop of middle dose PF-04217329, once a day, per dosed eye for duration of study.
Study: NCT00572455
Drug: PF-04217329 - High Middle Dose
Normalized name: Influenza, high-dose, quadrivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop of high middle dose PF-04217329, once a day, per dosed eye for duration of study.
Study: NCT00572455
Drug: PF-04217329 - High Dose
Normalized name: Influenza, high-dose, quadrivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop of high dose PF-04217329, once a day, per dosed eye for duration of study.
Study: NCT00572455
Drug: PF-4217329 - Highest Dose
Normalized name: Influenza, high-dose, quadrivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop of highest dose PF-04217329, once a day, per dosed eye for duration of study.
Study: NCT00572455
Drug: PF-04217329 - Middle Dose
Normalized name: Influenza, high-dose, quadrivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five minutes after latanoprost vehicle, 1 drop of middle dose PF-04217329, once a day, per dosed eye for duration of study.
Study: NCT00572455
Drug: PF-04217329 - High Dose
Normalized name: Influenza, high-dose, quadrivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five minutes after latanoprost vehicle, 1 drop of high dose PF-04217329, once a day, per dosed eye for duration of study.
Study: NCT00572455
Drug: PF-04217329 - Middle Dose
Normalized name: Influenza, high-dose, quadrivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five minutes after latanoprost 0.005%, 1 drop middle dose PF-04217329, once a day, per dosed eye for duration of study.
Study: NCT00572455
Drug: PF-04217329 - High Dose
Normalized name: Influenza, high-dose, quadrivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five minutes after latanoprost 0.005%, 1 drop high dose PF-04217329, once a day, per dosed eye for duration of study.
Study: NCT02824224
Drug: Placebo (for Tamoxifen)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic the tamoxifen 10mg tablet
Study: NCT02103023
Drug: Aqueous cream
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: aqueous cream
Study: NCT04152083
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection for IV administration
Study: NCT01001520
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be asked to take study medication each day for both 11-day study medication periods.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take tolcapone during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by tolcapone during the second medication period.
Study: NCT04061278
Drug: 4 cycles of Neoadjuvant Chemotherapy With Definitive Radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 Cycles of Neoadjuvant Chemotherapy With Definitive Radiotherapy, instead of Concurrent Chemoradiotherapy
Study: NCT04026230
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar capsules as in the atorvastatin arm, but without the active ingredient
Study: NCT03549598
Drug: 13NH3 PET/CT scan
Approvals — FDA: no, EMA: no, PMDA: no
Description: This scan will be performed as part of the planned clinical care for the patient. Dose of 13NH3 will be administered intravenously in accordance with the institutional policy and accepted norms. CT attenuation scan will also be performed as part of this examination per institutional protocol.
Study: NCT01300247
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive 6 cycles (each 28-day cycle) of cyclophosphamide at dose of 250 mg/m\^2 IV on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6.
Study: NCT01858207
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TACE will be done according to the current method in our center. We use intra-injection of lipiodol mized with doxorubicin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
Study: NCT04202965
Drug: PTG-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with PTG-300 injected subcutaneously.
Study: NCT00525473
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azathioprine usual dosage 100mg per day
Study: NCT00718094
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet: placebo